Comment from Biocom

Summary: Biocom, an advocacy organization representing California's life science sector, supports the FDA's goal of integrating New Approach Methodologies (NAMs) into drug development to reduce reliance on animal testing. They provide specific recommendations to improve the guidance's clarity regarding validation requirements, "weight of evidence" frameworks, and the integration of multiple NAMs.